FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802890120> ?p ?o ?g. }

• W2802890120 endingPage "230" @default.
• W2802890120 startingPage "222" @default.
• W2802890120 abstract "We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population." @default.
• W2802890120 created "2018-05-17" @default.
• W2802890120 creator A5000346346 @default.
• W2802890120 creator A5010837144 @default.
• W2802890120 creator A5012884395 @default.
• W2802890120 creator A5022030260 @default.
• W2802890120 creator A5023152679 @default.
• W2802890120 creator A5023312817 @default.
• W2802890120 creator A5027328800 @default.
• W2802890120 creator A5032464400 @default.
• W2802890120 creator A5043526996 @default.
• W2802890120 creator A5045740077 @default.
• W2802890120 creator A5046070614 @default.
• W2802890120 creator A5049711954 @default.
• W2802890120 creator A5051006606 @default.
• W2802890120 creator A5052048627 @default.
• W2802890120 creator A5055089118 @default.
• W2802890120 creator A5055832458 @default.
• W2802890120 creator A5075153453 @default.
• W2802890120 creator A5088396920 @default.
• W2802890120 creator A5089094849 @default.
• W2802890120 date "2018-05-08" @default.
• W2802890120 modified "2023-10-16" @default.
• W2802890120 title "A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma" @default.
• W2802890120 cites W1931544110 @default.
• W2802890120 cites W1955748620 @default.
• W2802890120 cites W1969648097 @default.
• W2802890120 cites W1998628488 @default.
• W2802890120 cites W2000069677 @default.
• W2802890120 cites W2003734726 @default.
• W2802890120 cites W2013370486 @default.
• W2802890120 cites W2020298011 @default.
• W2802890120 cites W2044436186 @default.
• W2802890120 cites W2049746143 @default.
• W2802890120 cites W2132080882 @default.
• W2802890120 cites W2139006680 @default.
• W2802890120 cites W2141105112 @default.
• W2802890120 cites W2142149038 @default.
• W2802890120 cites W2146000276 @default.
• W2802890120 cites W2160088903 @default.
• W2802890120 cites W2164667231 @default.
• W2802890120 cites W2164807675 @default.
• W2802890120 cites W2167571044 @default.
• W2802890120 cites W2169183166 @default.
• W2802890120 cites W2567188480 @default.
• W2802890120 cites W2570618306 @default.
• W2802890120 cites W2588657525 @default.
• W2802890120 cites W2606120108 @default.
• W2802890120 cites W2750658188 @default.
• W2802890120 cites W2752740163 @default.
• W2802890120 doi "https://doi.org/10.1111/bjh.15261" @default.
• W2802890120 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6074026" @default.
• W2802890120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29740809" @default.
• W2802890120 hasPublicationYear "2018" @default.
• W2802890120 type Work @default.
• W2802890120 sameAs 2802890120 @default.
• W2802890120 citedByCount "107" @default.
• W2802890120 countsByYear W28028901202018 @default.
• W2802890120 countsByYear W28028901202019 @default.
• W2802890120 countsByYear W28028901202020 @default.
• W2802890120 countsByYear W28028901202021 @default.
• W2802890120 countsByYear W28028901202022 @default.
• W2802890120 countsByYear W28028901202023 @default.
• W2802890120 crossrefType "journal-article" @default.
• W2802890120 hasAuthorship W2802890120A5000346346 @default.
• W2802890120 hasAuthorship W2802890120A5010837144 @default.
• W2802890120 hasAuthorship W2802890120A5012884395 @default.
• W2802890120 hasAuthorship W2802890120A5022030260 @default.
• W2802890120 hasAuthorship W2802890120A5023152679 @default.
• W2802890120 hasAuthorship W2802890120A5023312817 @default.
• W2802890120 hasAuthorship W2802890120A5027328800 @default.
• W2802890120 hasAuthorship W2802890120A5032464400 @default.
• W2802890120 hasAuthorship W2802890120A5043526996 @default.
• W2802890120 hasAuthorship W2802890120A5045740077 @default.
• W2802890120 hasAuthorship W2802890120A5046070614 @default.
• W2802890120 hasAuthorship W2802890120A5049711954 @default.
• W2802890120 hasAuthorship W2802890120A5051006606 @default.
• W2802890120 hasAuthorship W2802890120A5052048627 @default.
• W2802890120 hasAuthorship W2802890120A5055089118 @default.
• W2802890120 hasAuthorship W2802890120A5055832458 @default.
• W2802890120 hasAuthorship W2802890120A5075153453 @default.
• W2802890120 hasAuthorship W2802890120A5088396920 @default.
• W2802890120 hasAuthorship W2802890120A5089094849 @default.
• W2802890120 hasBestOaLocation W28028901201 @default.
• W2802890120 hasConcept C126322002 @default.
• W2802890120 hasConcept C141071460 @default.
• W2802890120 hasConcept C143998085 @default.
• W2802890120 hasConcept C2776063141 @default.
• W2802890120 hasConcept C2776364478 @default.
• W2802890120 hasConcept C2777478702 @default.
• W2802890120 hasConcept C2780401358 @default.
• W2802890120 hasConcept C2781413609 @default.
• W2802890120 hasConcept C2908647359 @default.
• W2802890120 hasConcept C2911091166 @default.
• W2802890120 hasConcept C71924100 @default.
• W2802890120 hasConcept C90924648 @default.
• W2802890120 hasConcept C99454951 @default.
• W2802890120 hasConceptScore W2802890120C126322002 @default.

• next